Oppenheimer Holdings led the funding round. The Series C brings Perspectum’s total amount raised since inception to about $120 million.
“We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients’ diagnostic and treatment journeys,” said Dr. Rajarshi Banerjee, CEO of Perspectum. “This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases.”
Perspectum develops medical imaging tools to improve the diagnosis of metabolic diseases and cancer. Its flagship diagnostic tool, LiverMultiScan, assesses and monitors chronic liver disease. The company said it plans to expand its footprint in the U.S. and grow its customer base. That effort includes a recent collaboration with Nuance, a Microsoft company, announced last month.
The software enhances the capabilities of standard MRI, Perspectum says. It enables the machine to capture multiparametric mapping data. That allows the AI-drive software to measure organ inflammation with greater precision.
Perspectum plans to use the Series C funds to scale its U.S. operations. It also intends to use some to accelerate its product pipeline for multiorgan inflammatory conditions and oncology.
“Perspectum is a truly disruptive company with medical imaging software that can dramatically improve the standard of care for millions of patients, as well as provide a higher level of decision support for physicians,” said Robert Lowenthal, president of Oppenheimer Holdings. “We anticipate Perspectum will continue to lead the field of AI-enhanced imaging for years to come.”